EUDA cuts Streeterville warrant exercise price

EUDA Health Holdings Limited reported that it has entered into a second amendment to its warrant agreement with Streeterville Capital, LLC.

Rhea-AI Filing Summary

EUDA Health Holdings Limited reported that it has entered into a second amendment to its warrant agreement with Streeterville Capital, LLC. The amendment, dated January 13, 2026, reduces the warrant exercise price from US$4.00 per share to US$2.00 per share and lowers the minimum closing price required to trigger a forced exercise from US$6.00 to US$3.00. All other warrant terms remain unchanged.

EUDA’s Chief Executive Officer, Alfred Lim, described the change as a technical adjustment intended to align the warrant terms with current market conditions and preserve flexibility in the company’s capital structure, while emphasizing that it does not alter EUDA’s long-term strategy or operational priorities in preventive and longevity-focused healthcare.

Insights

Capital structure and securities analyst

EUDA reprices a Streeterville warrant, easing exercise thresholds without changing other terms.

EUDA Health and Streeterville Capital amended an existing warrant by cutting its exercise price from US$4.00 to US$2.00 per share. The minimum closing price needed to trigger a forced exercise was also lowered from US$6.00 to US$3.00. These changes make it easier for the warrant to be exercised under lower share-price levels, while all other contractual terms stay the same.

From a capital-structure perspective, this adjustment can facilitate earlier or more likely warrant exercises if market prices move above the new thresholds, although the excerpt does not quantify the warrant size or potential proceeds. Management characterizes the move as a technical step to align with current market conditions and to preserve flexibility, stating that it does not alter the company’s long-term strategy or operational focus on preventive health, longevity solutions, and personalised healthcare.

The practical impact will depend on EUDA’s future share price relative to the new US$2.00 exercise level and the US$3.00 forced exercise trigger, as well as any subsequent disclosures on warrant usage and capital planning in future company communications.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did EUDA Health (EUDA) announce in this Form 6-K?

EUDA Health announced that it entered into a second amendment to its existing warrant agreement with Streeterville Capital, LLC, adjusting key pricing terms while leaving all other warrant provisions unchanged.

How did the Streeterville warrant exercise price change for EUDA Health (EUDA)?

Under the second amendment, the exercise price of the Streeterville warrant was reduced from US$4.00 per share to US$2.00 per share.

What is the new forced exercise trigger price for EUDA Healths Streeterville warrant?

The minimum closing price of EUDA Healths ordinary shares required to trigger a forced exercise under the warrant was lowered from US$6.00 to US$3.00.

Did EUDA Health change any other terms of the Streeterville warrant?

No. The company stated that, apart from reducing the exercise price and the forced exercise trigger price, all other terms of the Streeterville warrant remain unchanged.

How did EUDA Healths CEO describe the warrant amendment?

Chief Executive Officer Alfred Lim described the second amendment as a technical adjustment to align the warrant terms with current market conditions and to preserve flexibility in EUDAs capital structure, without changing its long-term strategy or operational priorities.

What is EUDA Healths core business focus?

EUDA Health is a Singapore-based non-invasive healthcare provider operating in Asia, focusing on Singapore, Malaysia and China, with a strategic emphasis on preventive healthcare and the fast-growing longevity sector, and it also runs a Singapore-based property management business.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/15/2026 - 04:30 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026

Commission File Number: 001-40678

EUDA Health Holdings Limited

(Exact Name of Registrant as Specified in its Charter)

60 Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: +65 6327 1110

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

Other Events.

On January 15, 2026, EUDA Health Holdings Limited issued the press release filed herewith as Exhibit 99.1.

Exhibits

99.1 Press release dated January 15, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Dated: January 15, 2026
EUDA Health Holdings Limited
By:	/s/ Alfred Lim
	Alfred Lim
	Chief Executive Officer

Exhibit 99.1

EUDA Health Announces Second Amendment to Streeterville Warrant Agreement

SINGAPORE, Jan. 15, 2026 (GLOBE NEWSWIRE) – EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it has entered into a second amendment to its previously disclosed warrant agreement with Streeterville Capital, LLC.

Summary of Second Warrant Amendment Terms

Under the terms of the Second Warrant Amendment dated January 13, 2026, the Company and Streeterville Capital agreed to further reduce the exercise price of the warrant from US$4.00 per share to US$2.00 per share. In addition, the minimum closing price of the Company’s ordinary shares required to trigger a forced exercise under the warrant was reduced from US$6.00 to US$3.00. All other terms of the warrant remain unchanged.

Mr Alfred Lim, Chief Executive Officer of EUDA, commented:

“We view this second amendment as a technical adjustment to align the warrant terms with current market conditions and to preserve flexibility in our capital structure. It does not change our long-term strategy or operational priorities, and we remain focused on executing our business plan across preventive health, longevity solutions, and personalised healthcare.”

About EUDA Health Holdings Limited

EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.

Forward-Looking Statements

This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Christensen Advisory

Christian Arnell

Phone: + 852 9040 0621

Email: christian.arnell@christensencomms.com